Company intelligence / Profile preview

NeuroLucent

North Chicago, Illinois, United States

Ownership: Private
Development stage: Other

Overview

NeuroLucent is an early-stage biotechnology company developing preclinical small-molecule ryanodine receptor modulators aimed at treating cognitive loss in Alzheimer's disease; its compounds have been validated in multiple disease models but have not yet reached clinical trials.[1][4][5]

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

PostEra

Beyond the preview

Go deeper on NeuroLucent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroLucent.

Explore the full profile